Showing results (101-110 of 128) with videos related to
Sort By:
Pageof 13
Clinical Lung Cancer|February 15, 2021
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400GTaofeek K Owonikoko, Mary W Redman, Lauren A Byers, et al.The Lancet. Oncology|November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 studyRoy S Herbst, Mary W Redman, Edward S Kim, et al.Cancer|December 9, 2022
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancerDiego de Miguel-Perez, Alessandro Russo, Muthukumar Gunasekaran, et al.Clinical Lung Cancer|November 22, 2020
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)Saiama N Waqar, Mary W Redman, Susanne M Arnold, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLCJonathan W Riess, David R Gandara, Garrett M Frampton, et al.Journal for Immunotherapy of Cancer|August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.Molecular Cancer Therapeutics|February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2014
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancerAmir Goldkorn, Benjamin Ely, David I Quinn, et al.International Journal of Cancer|September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trialAmir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.JAMA Oncology|July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical TrialScott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.Pageof 13